The Juveena Hydrogel System is designed as a temporary spacer to help prevent the formation and reformation of intrauterine adhesions (IUAs). The PMA submission includes results from a pivotal ...
Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately 121 out of every ...
The MarketWatch News Department was not involved in the creation of this content. ROSWELL, Ga., Oct. 15, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today ...
Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study. This announcement marks a ...
Credit: Shutterstock. By the end of the 6th year, Mirena should be removed and replaced if continued use is desired. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...
Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that ...
(RTTNews) - German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval ...
Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...
Low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg and 19.5 mg is associated with a significantly lower risk of first-time depression vs high dose LNG-IUS 52 mg. Overall, 46,565 ...
BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback